Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel vs Docetaxel for Neoadjuvant Breast Cancer
NCT05420454Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paclitaxel in breast cancer (4 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Pathological Complete Response at 1 year. Started Jul 2022; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05420454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420454.